GlassScriptPhysician profile
River Tammetta
NPI 1689387631
$3,558.43
in general payments reported to CMS, 2019-2025
19 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,349 · 2024: $1,943 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,558.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $700.01 | 2023-2025 | |
| Alkermes, INC. | $541.67 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $396.97 | 2023-2024 | Invega, Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $316.92 | 2023-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $310.72 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $294.35 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $217.72 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $139.50 | 2023-2024 | Nuedexta, Abilify Maintena, Rexulti |
| Tempus Ai, INC | $125.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $122.01 | 2024 | |
| Axsome Therapeutics, INC. | $83.84 | 2023-2024 | Auvelity |
| Indivior INC. | $83.71 | 2023 | Perseris |
| Bausch Health US, LLC | $55.65 | 2023-2024 | Aplenzin |
| Lundbeck LLC | $53.87 | 2023-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $36.92 | 2023-2024 | Trintellix |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $31.61 | 2023 | Quviviq |
| Revance Therapeutics, INC. | $18.15 | 2025 | Daxxify |
| Supernus Pharmaceuticals, INC. | $16.85 | 2024 | Qelbree |
| Corium, LLC | $12.96 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw River Tammetta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.